



Episode 5: Cutaneous Sarcoidosis - Part 2: screening for systemic involvement and treatment



Dr Sarah Walsh, Consultant Dermatologist at King's College Hospital, London.

In this episode we discuss:

- Screening questions and investigations to assess for the presence of systemic disease
- Treatment of cutaneous sarcoidosis
- Assessing disease response and monitoring

Cutaneous sarcoidosis treatment ladder:

First line:

Topical/intralesional/oral corticosteroids
Hydroxychloroquine/mepacrine

Second line:

Methotrexate
Azathioprine
Mycophenolate mofetil

+ Hydroxychloroquine

Other:

Anti-TNF
Anti IL12/23
JAK inhibitors

References and further reading:

- Judson, M.A., *The Clinical Features of Sarcoidosis: A Comprehensive Review*. Clin Rev Allergy Immunol, 2015. **49**(1): p. 63-78.
- Ungprasert, P., J.H. Ryu, and E.L. Matteson, *Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis*. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2019. **3**(3): p. 358-375.

- Sene, T., et al., *Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients*. J Am Acad Dermatol, 2012. **66**(2): p. 328-32.
- Yusuf, I.H., et al., *The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary*. Eye, 2018. **32**(7): p. 1168.
- Rosenbach, M., et al., *Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis*. JAMA Dermatol, 2013. **149**(5): p. 550-6.